1887

Abstract

Transmissible subacute spongiform encephalopathies (TSSE) are neurodegenerative diseases characterized by the presence of a modified, partially proteinase-resistant host protein, PrP, which accumulates in the brains of infected individuals. Recently it has been reported that amphotericin B (AmB) treatment of hamsters infected with scrapie strain 263K prolongs the incubation period of the disease, and dissociates replication of the scrapie agent from PrP accumulation. We report here on data obtained after treatment with AmB and one of its derivatives, MS-8209, in experimental scrapie of mouse and hamster. Treatment was carried out by the intraperitoneal route 6 days per week, at three different dosages initiated at the time of infection. Two regimens were used: during the early time of infection or throughout the experimental infection. Results indicate that MS-8209 was as efficient as AmB in prolonging the incubation time and decreasing PrP accumulation in the hamster scrapie model. A dose-dependent response was observed in mice treated early after experimental infection. At a dose of 2·5 mg/kg, MS-8209 significantly prolonged the incubation period (by 11·9%). In longterm treatment of mice, MS-8209 and AmB markedly reduced PrP levels in the preclinical stage of the disease. These data demonstrate that the effect of AmB is not restricted to one model (hamster-263K). This regimen leads to an inversion of the PrP to proteinase- sensitive protein (pp) ratio, suggesting PrP(presumably cellular PrP) accumulation occurs before its conversion into PrP. As it has been shown that AmB does not modify the infectivity titre, we conclude that the drugs could act by inhibiting either the interaction of the scrapie agent with PrP during the early times of infection or the conversion of PrP into PrP.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-75-9-2499
1994-09-01
2021-10-19
Loading full text...

Full text loading...

/deliver/fulltext/jgv/75/9/JV0750092499.html?itemId=/content/journal/jgv/10.1099/0022-1317-75-9-2499&mimeType=html&fmt=ahah

References

  1. Amyx H., Salazar A. M., Gajdusek D. C., Gibbs C. J. 1984; Chemotherapeutic trials in experimental slow virus disease. Neurology 34:149
    [Google Scholar]
  2. Bolton D. C., Mckinley M. P., Prusiner S. B. 1982; Identification of a protein that purifies with the scrapie prion. Science 218:1309–1311
    [Google Scholar]
  3. Brown P. 1990; A therapeutic panorama of the spongiform encaphalopathies. Antiviral Chemistry and Chemotherapy 1:75–83
    [Google Scholar]
  4. Büeler H., Aguzzi A., Sailer A., Greiner R. A., Autenried P., Aguet M., Weissmann C. 1993; Mice devoid of PrP are resistant to scrapie. Cell 73:1339–1347
    [Google Scholar]
  5. Caughey B., Raymond G. J. 1993; Sulfated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells. Journal of Virology 61:643–650
    [Google Scholar]
  6. Cefai D., Hadida F., Jung M., Debre P., Vernin J. G., Seman M. 1991; MS-8209, a new amphotericin B derivative that inhibits HIV-l replication in vitro and restores T-cell activation via the CD3/TcR in HIV infected CD4+cells. AIDS 5:1453–1458
    [Google Scholar]
  7. Dormont D., Delpech B., Delpech A., Courcel M. N., Viret J., Markovits P., Court L. 1981; Hyperproduction de proteine gliofibrillaire acide (GFAP) au cours de 1'evolution de la tremblante experimental de la souris. Comptes Rendus de I’Academie des Sciences de Paris 293:53–56
    [Google Scholar]
  8. Dormont D., Yeramian P., Lambert P., Cathala F., Spire B., Barre-Sinoussi F. C., Court L., Chermann J. C. 1986; In vitro and in vivo antiviral effects of HPA23. In Unconventional Virus Diseases of the Central Nervous System pp 324–337 Court L. A., Dormont D., Brown P., Kingsbury D. T. Edited by Paris: Masson;
    [Google Scholar]
  9. Ehlers B., Diringer H. 1984; Dextran sulphate 500 delays and prevents mouse scrapie by impairment of agent replication in spleen. Journal of General Virology 65:1325–1330
    [Google Scholar]
  10. Farquhar C. F., Dickinson A. G. 1986; Prolongation of scrapie incubation period by an injection of dextran sulphate 500 within the month before or after infection. Journal of General Virology 67:463–473
    [Google Scholar]
  11. Gibbs C. J., Gajdusek D. C., Morris J. A. 1964; Further observations in mice following inoculation of scrapie goat and sheep brain material. Report of Scrapie Seminar Washington, D.C., U.S.A:January 27–30 pp 292–297
    [Google Scholar]
  12. Kimberlin R. H. 1978; Discovery of treatments that enhance or suppress scrapie infection. Journal of Supramolecular Structure supplement 2:275
    [Google Scholar]
  13. Kimberlin R. H., Walker C. A. 1977; Characteristics of a short incubation model of scrapie in the golden hamster. Journal of General Virology 34:295–304
    [Google Scholar]
  14. Kimberlin R. H., Walker C. A. 1979; Pathogenesis of mouse scrapie: dynamics of agent replication in spleen, spinal cord and brain after infection by different routes. Journal of Comparative Pathology 89:551–562
    [Google Scholar]
  15. Lazarini F., Deslys J.-P., Dormont D. 1992; Variations in prion protein and glial fibrillary acidic protein mRNAs in the brain of scrapie-infected newborn mouse. Journal of General Virology 73:1645–1648
    [Google Scholar]
  16. Mackenzie A. 1983; Immunohistochemical demonstration of glial fibrillary acidic protein in scrapie. Journal of Comparative Pathology 93:251–259
    [Google Scholar]
  17. Medoff G., Brajtburg J., Kobayashi G. S., Bolard J. 1983; Antifungal agents useful in therapy of systemic fungal infections. Annual Review of Pharmacology and Toxicology 23:303–330
    [Google Scholar]
  18. Meyer R. K., Mckinley M. P., Bowman K. A., Braunfeld M. B., Barry R. A., Prusiner S. B. 1986; Separation and properties of cellular and scrapie prion proteins. Proceedings of the National Academy of Sciences U.S.A.: 832310–2314
    [Google Scholar]
  19. Oesch B., Westaway D., Walchli M., Mckinley M. P., Kent S. B., Aebersold R., Barry R. A., Tempst P., Teplow D. B., Hood L. E., Prusiner S. B., Weissmann C. 1985; A cellular gene encodes scrapie PrP 27-30 protein. Cell 40:735–746
    [Google Scholar]
  20. Pocchiari M., Schmittinger S., Masullo C. 1986; Effects of amphotericin B in intracerebrally scrapie inoculated hamster. In Unconventional Virus Diseases of the Central Nervous System pp 314–323 Court L. A., Dormont D., Brown P., Kingsbury D. T. Edited by Paris: Masson;
    [Google Scholar]
  21. Pocchiari M., Casaccia P., Ladogana A. 1989; Amphotericin B: a novel class of antiscrapie drugs. Journal of Infectious Diseases 160:795–802
    [Google Scholar]
  22. Prusiner S. B. 1982; Novel proteinaceous infectious particles cause scrapie. Science 216:136–144
    [Google Scholar]
  23. Prusiner S. B., Groth D., Serban A., Stahl N., Gabizon R. 1993; Attempts to restore scrapie prion infectivity after exposure to protein denaturants. Proceedings of the National Academy of Sciences U.S.A.: 902793–2797
    [Google Scholar]
  24. Serban D., Taraboulos A., Dearmond S. J., Prusiner S. B. 1990; Rapid detection of Creutzfeldt-Jakob disease and scrapie prion proteins. Neurology 40:110–117
    [Google Scholar]
  25. St Julien L., Joly V., Seman M., Carbon C., Yeni P. 1992; Activity of MS-8209, a nonester amphotericin B derivative, in treatment of experimental systemic mycoses. Antimicrobial Agents and Chemotherapy 36:2722–2728
    [Google Scholar]
  26. Stahl N., Baldwin M. A., Burlingame A. L., Prusiner S. B. 1990; Identification of glycoinositol phospholipid linked and truncated forms of the scrapie prion protein. Biochemistry 29:8879–8884
    [Google Scholar]
  27. Xi Y. G., Ingrosso L., Ladogana A., Masullo C., Pocchiari M. 1992; Amphotericin B treatment dissociates in vivo replication of the scrapie agent from PrP accumulation. Nature; London: 356598–601
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-75-9-2499
Loading
/content/journal/jgv/10.1099/0022-1317-75-9-2499
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error